Integrative Physiology |
From the Department of Medicine, University of Cambridge, Addenbrookes Hospital (D.P., L.H., M.R.B., C.M.H., P.L.W) and Department of Anatomy, Multi-Imaging Centre (J.N.S.), Cambridge, UK.
Correspondence to D. Proudfoot, Department of Medicine, University of Cambridge, Addenbrookes Hospital, Level 6, ACCI Building, Hills Rd, Cambridge CB2 2QQ, UK. E-mail dp{at}mole.bio.cam.ac.uk
| Abstract |
|---|
|
|
|---|
28 days. Apoptosis occurred before the onset of
calcification in VSMC nodules and was detected by several methods,
including nuclear morphology, the TUNEL technique, and external display
of phosphatidyl serine. Inhibition of apoptosis with the caspase
inhibitor ZVAD.fmk reduced calcification in nodules by
40%, as
measured by the cresolphthalein method and alizarin red staining. In
addition, when apoptosis was stimulated in nodular cultures with
anti-Fas IgM, there was a 10-fold increase in calcification.
Furthermore, incubation of VSMC-derived apoptotic bodies with
45Ca demonstrated that, like matrix
vesicles, they can concentrate calcium. These observations provide
evidence that apoptosis precedes VSMC calcification and that apoptotic
bodies derived from VSMCs may act as nucleating structures for calcium
crystal formation.
Key Words: calcification vascular smooth muscle apoptosis apoptotic bodies
| Introduction |
|---|
|
|
|---|
Matrix vesicles are thought to initiate calcification in forming bone and mineralizing cartilage.10 These are membrane-bound vesicles that are produced by budding from chondrocytes, osteoblasts, and odontoblasts and contain the necessary calcium-binding proteins and phosphatases for nucleation of hydroxyapatite. Matrix vesicle-like structures have also been found in calcified arteries and heart valves.11 12 Kockx et al13 showed that in advanced carotid atherosclerotic plaques, these structures were derived from vascular smooth muscle cells (VSMCs) and contained BAX protein, a proapoptotic member of the bcl-2 family, indicating that they may be remnants of apoptotic cells. It is thought that cell death may lead to matrix vesicle generation,10 14 and Hashimoto et al15 recently demonstrated that chondrocyte apoptotic bodies have similarities with matrix vesicles.
We have previously shown that human VSMCs spontaneously form
multicellular nodules and deposit calcium crystals after
28 days in
culture and that, by using electron microscopy, matrix vesicle-like
structures can be identified within the
nodules.16 In the present
study, we have established that apoptosis occurs in VSMC nodules and
have tested the hypothesis that apoptosis initiates calcification by
inhibiting VSMC apoptosis with the cell-permeable caspase-inhibitor
ZVAD.fmk. We demonstrate that inhibiting apoptosis also inhibits
calcification. In addition, stimulation of apoptosis with a combination
of anti-Fas IgM and cycloheximide increased nodule calcification.
Furthermore, we have shown that apoptotic bodies derived from cultured
human VSMCs can concentrate and crystallize calcium. These studies
provide experimental evidence for the first time, to our knowledge, to
show that apoptosis precedes calcification and that apoptotic bodies
are capable of initiating vascular
calcification.
| Materials and Methods |
|---|
|
|
|---|
Induction of Apoptosis and Apoptotic Body
Preparation
Induction of apoptosis in VSMCs was achieved by
either addition of anti-Fas IgM (100ng/mL, clone CH11, Upstate
Biotechnology) and cycloheximide (10 µg/mL, Sigma) in serum-free M199
to primary human VSMCs for 24 hours or by serum starvation of a human
coronary plaque cell line HASMC 66 (human coronary artery smooth
muscle cell).17 Apoptotic
bodies (ABs) were harvested from these cultures by centrifugation of
cell supernatants at 2500 rpm.
Detection of Apoptosis
Nuclear Morphology
Nodules were cultured in 35-mm dishes in M199
containing 20% FCS and monitored live at 37°C. Bisbenzimide 2
µg/mL (final concentration, Hoechst No. 33258, Sigma) was added to
the medium, and the nodules were monitored by confocal microscopy
(Leica TCS-MP) so that the whole nodule could be imaged. Apoptotic
cells were quantified by counting fragmented or condensed nuclei by
capturing serial optical sections through the nodules. For this
analysis, the glow-over mode was used, because this gave the best
contrast between saturated and nonsaturated
fluorescence.
TUNEL Labeling
TUNEL labeling was performed on nodule sections
pretreated with citric acid, as described
previously.18
Phosphatidyl Serine Exposure
Nodules were treated as described above while being
monitored by time-lapse confocal microscopy. Annexin V-FITC (4 µL/mL,
Clontech) and propidium iodide (500 nmol/L, Clontech) were added to the
culture medium and monitored for initiation of annexin V
binding.
Detection of Calcification in Multicellular
Nodules
VSMCs were grown in 12-well plates fixed in 4%
formaldehyde in PBS for 45 minutes at 4°C. The cultures were then
washed in distilled water and exposed to alizarin red (2% aqueous,
Sigma) for 5 minutes and then washed again with distilled water.
Alternatively, the calcified material in each well was extracted from
nonfixed cell layers with 0.1 mol/L HCl overnight at room temperature
and quantified using
cresolphthalein.19 20
45Ca Accumulation
into ABs
To measure calcium accumulation in ABs, the method of
Hashimoto et al15 was used
and modified minimally. The calcifying reaction mixture contained
45Ca (
50 000 cpm) and 40 µg of ABs,
and the samples were incubated at 37°C for 24 hours. The samples were
then centrifuged at 6500 rpm for 10 minutes, and washed pellets were
dissolved in 0.1 mol/L HCl and then placed in HiSafe scintillation
fluid. Disodium ATP (100% pure, Roche) and Nonidet P-40 (NP-40, Sigma)
were included in some experiments. A synthetic cartilage lymph
calcification buffer was also used in some
experiments.21
Energy Dispersive X-ray Microanalysis
Adherent ABs mounted on thermonox discs were rinsed
in distilled water, quench-frozen in melting propane, and freeze-dried.
Elemental content of ABs was performed by energy dispersive x-ray (EDX)
in a Philips XL30-FEG system equipped with an Oxford Instrument ISIS,
GEM spectrometer.
Calcium Detection by Confocal
Microscopy
ABs were cultured in 35-mm dishes and incubated with
calcein-AM (2 µmol/L, Molecular Probes) for 30 minutes. ABs were then
washed 3 times in serum-free medium, and green fluorescence was
examined using the confocal microscope.
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
|
Detection of Apoptosis in Nodules
To find out whether apoptosis occurred in VSMC nodules,
several different methods were used. Stains including hematoxylin and
eosin (H&E) and Hoechst revealed many nuclei with condensed or
fragmented nuclei within nodules
(Figures 2A
through 2C). The TUNEL method was also used, which
detects DNA breaks characteristic of apoptosis. Several nuclei stained
positively by this method
(Figure 2D
), indicating that they are likely to have been
apoptotic. However, because TUNEL can potentially detect nonapoptotic
cells,22 23 we
also investigated exposure of phosphatidyl serine (PS) by cells in
nodules. Several PS-exposing cells were observed within and on the
periphery of the nodule, and many cells had already died, as indicated
by propidium iodide staining
(Figure 2F
). In addition, in nodules monitored by time-lapse
video microscopy, we observed cells within nodules undergoing surface
membrane blebbing, characteristic of apoptosis (data not shown).
Collectively, these results confirm that many cells within the nodule
undergo apoptosis by day 7 of nodule culture.
|
We previously observed that calcification was not detected
in nodules until day 28 of
culture.16 Because apoptosis
was evident before the onset of calcification, we investigated the
relationship between apoptosis and calcification by estimating the
apoptotic indices in nodules over the 28-day culture. To obtain an
accurate measure of the whole nodule apoptotic events, nodules were
optically sectioned using the confocal microscope. Apoptotic cells were
visualized using Hoechst nuclear morphology, ie, fragmented or
condensed nuclei were counted and an index was generated as the
percentage of apoptotic cells compared with total nodular cell number.
This analysis showed that the apoptotic index did not significantly
change between days 7 and 21 but increased at day 28
(Figure 3
). Therefore, apoptosis occurs before calcium
crystals are deposited, and the higher rates of apoptosis coincide with
the onset of calcification.
|
The apoptotic indices measured in nodules at various time
points were relatively high (>20%), which would predict that older
nodules would eventually become acellular. However, nodules cultured
for 8 weeks still contained viable cells, mainly peripherally
(Figure 1D
). By observing nodules with time-lapse
videomicroscopy, we found that nodules recruit cells from the
surrounding monolayer (data not shown). Therefore,
although the rate of apoptosis in nodules is relatively high, migration
of VSMCs into nodules accounts for the maintenance of
cellularity.
Effect of ZVAD.fmk on Calcification
To confirm that the caspase inhibitor ZVAD.fmk had an
antiapoptotic effect in VSMC nodules, its effects on nodule apoptosis
were measured using Hoechst, as in Figure 3
. ZVAD.fmk (100 µmol/L)
decreased the apoptotic index in day-7 nodules, from 39.1±7.5% in the
control nodules to 28.0±9.6% in treated nodules (n=6,
P=0.03). Examples of optical
sections of nodules treated with or without ZVAD.fmk are shown in
Figure 4
. To test the possibility that ZVAD.fmk affected
cell proliferation, Ki-67 staining was performed on nodule sections,
but no difference was seen between control and ZVAD.fmk-treated groups
(see the online data supplement, available at
http://www.circresaha.org.). Also, we did not observe an effect of
ZVAD.fmk on necrotic cell death in VSMCs (data not shown).
|
After verification of the antiapoptotic effects of ZVAD.fmk
on nodule apoptosis, ZVAD.fmk (100 µmol/L) was added throughout the
28-day culture period, and its effects on subsequent calcification were
measured. Treatment with ZVAD.fmk reduced the amount of calcification
in nodular cultures, as assessed by alizarin red staining
(Figures 5A
and 5B
) as well as calcium content in the nodular
cultures
(Figure 5C
). It is important to note that the presence of
ZVAD.fmk had no effect on the total number of nodules. Therefore,
inhibition of apoptosis in nodules with ZVAD.fmk reduced the resulting
nodule calcification.
|
Effect of Enhancing Apoptosis in
Nodules
The role of apoptosis was investigated additionally by
exposure of the nodular cultures to apoptotic stimuli: a combination of
anti-Fas IgM and cycloheximide. Treatment of VSMC nodular cultures with
anti-Fas IgM and cycloheximide significantly increased the total amount
of calcium deposited in cultures by
10-fold
(Figure 6
).
|
Accumulation of Calcium by VSMC-Derived
ABs
To find out whether ABs derived from VSMCs could
accumulate calcium in a similar manner to chondrocyte ABs and matrix
vesicles,15 HASMC 66 cells
and primary VSMCs were used to generate ABs
(Figure 7A
). When VSMC-derived ABs were incubated in
calcifying medium, they accumulated 45Ca
from solution
(Figure 7B
).45Ca accumulation was
not stimulated by ATP (1 mmol/L), but ABs pretreated with the detergent
NP-40 to permeabilize the AB membrane failed to accumulate
45Ca
(Figure 7B
). These studies showed that ABs can concentrate
45Ca by a mechanism that requires an intact
AB membrane.
|
Elemental Analysis of VSMC ABs
To investigate the type of calcium deposited in ABs,
ABs were incubated in calcifying medium for 24 hours at 37°C and
analyzed for their elemental content by EDX
(Figures 8A
and 8B
). In both preparations there was a large
signal for Ca2+, confirming that ABs
concentrate calcium, but a low signal for phosphate. The backscattered
image suggests that the calcium is in a concentrated, crystallized form
and, from the elemental profile, is most likely to consist of calcium
carbonate. Thus, VSMC-derived ABs are capable of concentrating and
crystallizing calcium, which is distributed throughout the AB with
occasional voids
(Figure 8C
).
|
| Discussion |
|---|
|
|
|---|
The occurrence of apoptosis in our in vitro calcification
model was confirmed by several methods, including ultrastructural
characteristics, TUNEL, and PS exposure in VSMC nodular cells. At the
day-7 stage of nodule development, there was a mixture of apoptotic
cells, viable cells, and cells with damaged cell membranes. The
propidium iodidepositive cells at this stage may have been the result
of apoptosis (ie, secondary necrosis) or primary necrosis within the
nodules. Apoptosis occurred early in VSMC nodules, but we have
previously shown that calcium crystal deposition is not detected until
day 28 by von Kossa staining or
EDX.16 At the 28-day time
point, the apoptotic index increased, coinciding with detection of
calcification. These observations show that apoptosis precedes the
onset of calcium crystal formation but that if apoptosis initiates
calcification, its effects are delayed in early nodules, which would
imply that the calcification process in nodules is regulated. Possible
calcification-limiting factors produced by VSMCs in the nodule are
mineralization-regulating proteins, such as matrix Gla
protein.16 Another
possibility is that if ABs are the initiators of calcification, the
cells within the early nodules would be expected to recognize and
phagocytose the ABs.25 Older
nodules may contain less-efficient phagocytes, allowing the ABs to
stimulate calcium crystal growth. In support of a role for apoptosis in
calcification, other studies in cultured cells have shown associations
with apoptosis and calcification. Apoptosis occurred in cultures of
chick embryonal limb bud mesenchymal cells, which were used as a model
of chondrocyte
differentiation,26 and Lynch
et al27 have shown that
apoptosis is an integral part of osteoblast differentiation and
calcification in fetal rat calvarial osteoblast cultures.
To test whether apoptosis was actually required for calcification to occur, apoptosis was inhibited in nodules by the caspase inhibitor ZVAD.fmk. Alizarin red staining and calcium quantitation clearly showed that ZVAD.fmk inhibited calcification in VSMC nodules. ZVAD.fmk is a broad-spectrum inhibitor of caspases, and we confirmed its antiapoptotic effects in VSMC nodules. Other studies28 have shown that the mechanism of action of ZVAD.fmk is to prevent completion of the apoptotic program, which may not involve a delay in the onset of apoptosis. Caspase inhibition can also inhibit the release of ABs from cells.29 The role of apoptosis in our in vitro calcification model was then additionally examined by stimulating apoptosis in nodules with anti-Fas IgM and cycloheximide. This treatment resulted in a 10-fold stimulation of calcification, which strongly supports the role of apoptosis in calcification.
Role of VSMC-Derived ABs in Initiating
Calcification
Because a lack of clearance of ABs was a potential
mechanism of induction of calcification in VSMC nodules, we were
tempted to speculate that ABs derived from VSMCs could initiate
calcification in a similar manner to chondrocyte matrix vesicles or
ABs.15 We demonstrated that
VSMC-derived ABs accumulated calcium via a mechanism that involved an
intact AB membrane, because when it was permeabilized with NP-40, no
calcium accumulation was observed. The induction of calcium
accumulation in chondrocyte-derived matrix vesicles and ABs was
dependent on the presence of
ATP.15 However, ATP had no
effect on VSMC AB calcium uptake. In fact, the role of ATP in
calcification is not clear, because in different studies, ATP had
stimulatory effects on
calcification,15 was not
necessary for matrix vesicle
calcification,21 or
inhibited calcification.30
The lack of dependency on ATP for calcium uptake into VSMC ABs suggests
the following: calcium is taken up into VSMC ABs by an ion channel or
calcium-binding protein that does not require ATP for its activity; ABs
may contain sufficient ATP to accumulate calcium, and by adding
exogenous ATP, there is no additive effect; and VSMC ABs may not
contain the necessary enzymes for ATP hydrolysis, which are present in
matrix vesicles.31 PS
exposure by ABs generates a potential calcium-binding
site32 as well as a membrane
surface suitable for hydroxyapatite
deposition.33 However,
confocal images of cross sections of ABs loaded with calcein suggested
that calcium was concentrated throughout the AB rather than bound at
the membrane.
Elemental analysis of the bodies in calcifying solutions
revealed that they contained abundant calcium but very low phosphate.
The EDX spectra suggested that calcium carbonate may be the form of
calcium present in ABs. Calcium carbonate comprises
9% of the total
calcium crystals in human atherosclerotic
lesions,7 and carbonate
apatite is found in bone as well as ectopic
calcification.34 Calcium
carbonate can also act as a precursor to carbonate apatite formation
under certain conditions.35
These observations suggest that VSMC-derived ABs can concentrate and
crystallize calcium in a form that is found in vivo. Therefore, VSMC
ABs have similarities with chondrocyte-derived matrix vesicles but
produce a different type of calcium crystal in vitro. This may be
attributable to differences in in vitro culture conditions or perhaps
to intrinsic differences in protein expression.
It is interesting to note that not all chondrocyte matrix vesicles calcify, only those at specific sites in the cartilage matrix.21 Matrix vesicles in vitro will only calcify if they are preincubated in ascorbate- and phosphate-rich medium, which generates matrix vesicles enriched with annexin V (which can act as a Ca2+ channel) and alkaline phosphatase.21 These observations suggest that matrix vesicles are not all equivalent and that only tissues normally engaged in mineralization produce mineralization-competent vesicles. However, it is also possible that nonmineralizing tissues produce inhibitors of matrix vesicle function to block mineralization.21 Therefore, one can hypothesize that a lack of production of inhibitors of matrix vesicle calcification may lead to the development of pathological calcification.
Relevance of Apoptosis to Calcification in
Disease
Some studies have implied that ABs in atherosclerotic
plaques are similar to matrix vesicles and that these may initiate
calcification.23 24 36
In an electron microscopic study by
Stary,37 atherosclerotic
plaques were described as containing lipid-laden VSMCs, which shed
calcifying membrane-bound vesicles. In addition, although calcification
in atherosclerosis has been detected mainly in association with
extracellular structures such as matrix vesicles and extracellular
matrix, intracellular calcification has also been
observed.12 37
These may be calcified cell organelles or calcified structures that
have been engulfed by VSMCs.
If the matrix vesicle-like structures in plaques are apoptotic remnants, they should be rapidly cleared by adjacent phagocytic macrophages or VSMCs. In the largely acellular lipid core, phagocytosis may be impaired because of the presence of oxidized lipids that have been shown to compete with ABs for binding to phagocytes.38 Nonphagocytosed ABs would either undergo secondary necrosis or could proceed to calcify, depending on their local environment. Therefore, the presence of efficient phagocytic cells in atherosclerotic lesions is important for effective scavenging and, thereby, regulation of calcium deposition. This concept was tested experimentally by Kim,39 who demonstrated that rat aortic segments calcified when placed in Millipore chambers in the peritoneal cavity, but when aortic segments were grafted and contained inflammatory cells, calcification was minimal. Finally, in support of the role of apoptosis in calcification in vivo, mice lacking matrix Gla protein or osteoprotegerin develop medial vascular calcification and both proteins have potential roles in apoptosis.40 41
In summary, we have shown that apoptosis precedes human vascular calcification in vitro and that VSMC-derived ABs can concentrate and crystallize calcium. Therefore, what remains to be tested is whether a lack of phagocytosis of ABs leads to the progression of vascular calcification.
| Acknowledgments |
|---|
This work was supported by a British Heart Foundation program grant. Confocal microscopy and EDX were carried out in the Multi-Imaging Center in Cambridge, UK, which was established with funding from the Wellcome Trust (grant 055203/Z/98).
Received July 5, 2000; revision received October 18, 2000; accepted October 18, 2000.
| References |
|---|
|
|
|---|
2. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM. Coronary risk-factors measured in childhood and young-adult life are associated with coronary-artery calcification in young-adults: the Muscatine Study. J Am Coll Cardiol. 1996;27:277284.[Abstract]
3. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther. 1964;92:865871.[Medline] [Order article via Infotrieve]
4. Sharma SK, Israel DH, Kamean JL, Bodian CA, Ambrose JA. Clinical, angiographic, and procedural determinants of major and minor coronary dissection during angioplasty. Am Heart J. 1993;126:3947.[Medline] [Order article via Infotrieve]
5.
Wexler L, Brundage
B, Crouse J. Coronary artery calcification: pathophysiology,
epidemiology, imaging methods, and clinical applications.
Circulation. 1996;94:11751192.
6. Schmid K, McSharry WO, Pameijer CH, Binnette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37:199210.[Medline] [Order article via Infotrieve]
7. Shanahan CM, Cary NRB, Metcalf JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:23932402.
8.
Demer LL, Tintut Y.
Osteopontin: between a rock and a hard plaque.
Circ Res. 1999;84:250252.
9.
Giachelli CM.
Ectopic calcification: gathering hard facts about soft tissue
calcification. Am J
Pathol. 1998;154:671675.
10. Anderson HC. Molecular biology of matrix vesicles. Clin Orthop. 1995;314:266280.
11. Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med. 1983;172:173177.[Medline] [Order article via Infotrieve]
12. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc. 1976;35:156162.[Medline] [Order article via Infotrieve]
13.
Kockx MM, DeMeyer
GRY, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related
proteins in different stages of human atherosclerotic plaques.
Circulation. 1998;97:23072315.
14. Kim KM. Apoptosis and calcification. Scanning Microscopy. 1995;9:11371178.[Medline] [Order article via Infotrieve]
15.
Hashimoto S, Ochs
RL, Rosen F, Quach J, McCabe G, Solan J, Seegmiller JE, Terkeltaub
R, Lotz M. Chondrocyte-derived apoptotic bodies and calcification of
articular cartilage. Proc Natl Acad Sci
U S A. 1998;95:30943099.
16.
Proudfoot D,
Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular
cells in vitro is correlated with high levels of matrix Gla protein and
low levels of osteopontin expression.
Arterioscler Thromb Vasc Biol. 1998;18:379388.
17. Bennett MR, Evan GI, Scwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:22662274.
18. Hegyi L, Skepper JN, Cary NRB, Mitchinson MJ. Foam cell apoptosis and the development of the lipid core of human atherosclerosis. J Pathol. 1996;180:423429.[Medline] [Order article via Infotrieve]
19. Gitelman HJ. An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem. 1967;18:521531.
20.
Wada T, McKee MD,
Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell
cultures: inhibition by osteopontin. Circ
Res. 1999;84:166178.
21.
Kirsch T, Nah HD,
Shapiro IM, Pacifici M. Regulated production of
mineralisation-competent matrix vesicles in hypertrophic chondrocytes.
J Cell Biol. 1997;137:11491160.
22. Hegyi L, Hardwick SJ, Mitchinson MJ, Skepper JN. Letter. Am J Pathol. 1997;150: 371372.
23.
Kockx MM.
Apoptosis in the atherosclerotic plaque: quantitative and qualitative
aspects. Arterioscler Thromb Vasc
Biol. 1998;18:15191522.
24. Kockx MM, Muhring J, Bortier H, De Meyer GRY, Jacob W. Biotin- or Digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am J Pathol. 1996;148:17711777.[Abstract]
25.
Bennett MR,
Gibson DF, Schwartz SM, Tait JF. Binding and phagocytosis of apoptotic
vascular smooth muscle cells is mediated in part by exposure of
phosphatidyl serine. Circ Res. 1995;77:11361142.
26. Mello MA, Tuan RS. High density micromass cultures of embryonic limb bud mesenchymal cells: an in vitro model of endochondral skeletal development. Cell Dev Biol. 1999;35:262269.
27. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. Apoptosis during bone-like tissue development in vitro. J Cell Biochem. 1998;68:3149.[Medline] [Order article via Infotrieve]
28.
McCarthy NJ,
White MKB, Gilbert CS, Evan GI. Inhibition of Ced-3/ICE-related
proteases does not prevent cell death induced by oncogenes, DNA damage,
or the Bcl-2 homologue Bak. J Cell
Biol. 1997;136:215227.
29.
Zhang J, Reedy
MC, Hannun YA, Obeid LM. Inhibition of caspases inhibits the release of
apoptotic bodies: Bcl-2 inhibits the initiation of formation of
apoptotic bodies in chemotherapeutic agent-induced apoptosis.
J Cell Biol. 1999;145:99108.
30. Blumenthal NC. Mechanism of inhibition of calcification. Clin Orthop. 1989;247:279289.
31. Hsu HHT, Camacho NP, Anderson HC. Further characterisation of ATP-initiated calcification by matrix vesicles isolated from rachitic rat cartilage: membrane perturbation by detergents and deposition of calcium pyrophosphate by rachitic matrix vesicles. Biochim Biophys Acta. 1999;1416:320332.
32.
Cotmore JM,
Nichols G, Wuthier RE. Phospholipid-calcium phosphate complex: enhanced
calcium migration in the presence of phosphate.
Science. 1971;172:13391341.
33. Skrtic D, Eanes ED. Membrane mediated precipitation of calcium phosphate in model liposomes with matrix vesicle-like lipid composition. Bone Miner. 1992;16:109119.[Medline] [Order article via Infotrieve]
34. LeGeros RZ. Apatite in biological systems. Prog Crystal Growth Charact. 1981;4:145.
35. LeGeros RZ, Go P, Vandemaele KH, Quirolgico GB, LeGeros DJ. Transformation of calcium carbonates and calcium phosphates to carbonate apatites: possible mechanism for phosphorite formation. In: Proceedings 2nd International Congress on Phosphorous Compounds, April 2125, 1980, Boston, Mass. Morocco: Institut de Mondial de Phosphat; 1980:4154.
36.
Bauriedel G,
Huuter R, Welsch U, Bach R, Sievert H, Lüderitz B. Role of smooth
muscle cell death in advanced coronary primary lesions: implications
for plaque instability. Cardiovasc
Res. 1999;41:480488.
37. Stary HC. Atlas of Atherosclerosis: Progression and Regression. New York, NY: Parthenon; 1999.
38.
Bird DA, Gillotte
KL, Hörkkö S, Friedman P, Dennis EA, Witztum JL, Steinberg D.
Receptors for oxidised low-density lipoprotein on elicited mouse
peritoneal macrophages can recognize both the modified lipid moieties
and the modified protein moieties: implications with respect to
macrophage recognition of apoptotic cells.
Proc Natl Acad Sci
U S A. 1999;96:63476352.
39. Kim KM. Matrix vesicle calcification of rat aorta in Millipore chambers. Met Bone Dis Rel Res. 1978;1:213217.
40. Luo GDP, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature. 1997;386:7881.[Medline] [Order article via Infotrieve]
41.
Bucay N,
Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan
HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient
mice develop early onset osteoporosis and arterial calcification.
Genes Dev. 1998;12:12601268.
This article has been cited by other articles:
![]() |
M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Y. Yip, J.-H. Chen, R. Zhao, and C. A. Simmons Calcification by Valve Interstitial Cells Is Regulated by the Stiffness of the Extracellular Matrix Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 936 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Gu and K. S. Masters Role of the MAPK/ERK pathway in valvular interstitial cell calcification Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1748 - H1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Shroff, R. McNair, N. Figg, J. N. Skepper, L. Schurgers, A. Gupta, M. Hiorns, A. E. Donald, J. Deanfield, L. Rees, et al. Dialysis Accelerates Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell Apoptosis Circulation, October 21, 2008; 118(17): 1748 - 1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F Escobar-Morreale, J. I Botella-Carretero, M. A. Martinez-Garcia, M. Luque-Ramirez, F. Alvarez-Blasco, and J. L S. Millan Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome Eur. J. Endocrinol., September 1, 2008; 159(3): 225 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Danziger Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1504 - 1510. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Hsu, Y. Tintut, and L. L. Demer Vitamin D and Osteogenic Differentiation in the Artery Wall Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1542 - 1547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Ewence, M. Bootman, H. L. Roderick, J. N. Skepper, G. McCarthy, M. Epple, M. Neumann, C. M. Shanahan, and D. Proudfoot Calcium Phosphate Crystals Induce Cell Death in Human Vascular Smooth Muscle Cells: A Potential Mechanism in Atherosclerotic Plaque Destabilization Circ. Res., August 29, 2008; 103(5): e28 - e34. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C.H. Clarke, T. D. Littlewood, N. Figg, J. J. Maguire, A. P. Davenport, M. Goddard, and M. R. Bennett Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration Circ. Res., June 20, 2008; 102(12): 1529 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liberman, E. Bassi, M. K. Martinatti, F. C. Lario, J. Wosniak Jr, P. M.A. Pomerantzeff, and F. R.M. Laurindo Oxidant Generation Predominates Around Calcifying Foci and Enhances Progression of Aortic Valve Calcification Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 463 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice Circulation, January 22, 2008; 117(3): 411 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Villa-Bellosta, Y. E. Bogaert, M. Levi, and V. Sorribas Characterization of Phosphate Transport in Rat Vascular Smooth Muscle Cells: Implications for Vascular Calcification Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1030 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Norja, L. Nuutila, P. J Karhunen, and S. Goebeler C-reactive protein in vulnerable coronary plaques J. Clin. Pathol., May 1, 2007; 60(5): 545 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Schurgers, H. M. H. Spronk, B. A. M. Soute, P. M. Schiffers, J. G. R. DeMey, and C. Vermeer Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats Blood, April 1, 2007; 109(7): 2823 - 2831. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D.M. Collett, A. P. Sage, J. P. Kirton, M. Y. Alexander, A. P. Gilmore, and A. E. Canfield Axl/Phosphatidylinositol 3-Kinase Signaling Inhibits Mineral Deposition by Vascular Smooth Muscle Cells Circ. Res., March 2, 2007; 100(4): 502 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Johnson, J. A. Leopold, and J. Loscalzo Vascular Calcification: Pathobiological Mechanisms and Clinical Implications Circ. Res., November 10, 2006; 99(10): 1044 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Bennett, M. Scatena, E. A. Kirk, M. Rattazzi, R. M. Varon, M. Averill, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2117 - 2124. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Shanahan Vascular calcification--a matter of damage limitation? Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1166 - 1169. [Full Text] [PDF] |
||||
![]() |
B.-K. Son, K. Kozaki, K. Iijima, M. Eto, T. Kojima, H. Ota, Y. Senda, K. Maemura, T. Nakano, M. Akishita, et al. Statins Protect Human Aortic Smooth Muscle Cells From Inorganic Phosphate-Induced Calcification by Restoring Gas6-Axl Survival Pathway Circ. Res., April 28, 2006; 98(8): 1024 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, H.-Y. Yang, and C. M. Giachelli Role of the Sodium-Dependent Phosphate Cotransporter, Pit-1, in Vascular Smooth Muscle Cell Calcification Circ. Res., April 14, 2006; 98(7): 905 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. V. Bobryshev, R. S. A. Lord, and D. Tran Chlamydia pneumoniae in foci of "early" calcification of the tunica media in arteriosclerotic arteries: an incidental presence? Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1510 - H1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abedin, J. Lim, T.B. Tang, D. Park, L.L. Demer, and Y. Tintut N-3 Fatty Acids Inhibit Vascular Calcification Via the p38-Mitogen-Activated Protein Kinase and Peroxisome Proliferator-Activated Receptor-{gamma} Pathways Circ. Res., March 31, 2006; 98(6): 727 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Reynolds, J. N. Skepper, R. McNair, T. Kasama, K. Gupta, P. L. Weissberg, W. Jahnen-Dechent, and C. M. Shanahan Multifunctional Roles for Serum Protein Fetuin-A in Inhibition of Human Vascular Smooth Muscle Cell Calcification J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2920 - 2930. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Schurgers, K. J.F. Teunissen, M. H.J. Knapen, M. Kwaijtaal, R. van Diest, A. Appels, C. P. Reutelingsperger, J. P.M. Cleutjens, and C. Vermeer Novel Conformation-Specific Antibodies Against Matrix {gamma}-Carboxyglutamic Acid (Gla) Protein: Undercarboxylated Matrix Gla Protein as Marker for Vascular Calcification Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1629 - 1633. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Hruska, S. Mathew, and G. Saab Bone Morphogenetic Proteins in Vascular Calcification Circ. Res., July 22, 2005; 97(2): 105 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rattazzi, B. J. Bennett, F. Bea, E. A. Kirk, J. L. Ricks, M. Speer, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice: Potential Role of Chondrocyte-Like Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1420 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rosner, N. McCarthy, and M. Bennett Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53 Cardiovasc Res, June 1, 2005; 66(3): 601 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Giachelli, M. Y. Speer, X. Li, R. M. Rajachar, and H. Yang Regulation of Vascular Calcification: Roles of Phosphate and Osteopontin Circ. Res., April 15, 2005; 96(7): 717 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 773 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakazawa, T. Chiba, E. Kaneko, K. Yui, M. Yoshida, and K. Shimokado Insulin Signaling in Arteries Prevents Smooth Muscle Apoptosis Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 760 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Radcliff, T.-B. Tang, J. Lim, Z. Zhang, M. Abedin, L. L. Demer, and Y. Tintut Insulin-Like Growth Factor-I Regulates Proliferation and Osteoblastic Differentiation of Calcifying Vascular Cells via Extracellular Signal-Regulated Protein Kinase And Phosphatidylinositol 3-Kinase Pathways Circ. Res., March 4, 2005; 96(4): 398 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Giachelli Vascular Calcification Mechanisms J. Am. Soc. Nephrol., December 1, 2004; 15(12): 2959 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Reynolds, A. J. Joannides, J. N. Skepper, R. McNair, L. J. Schurgers, D. Proudfoot, W. Jahnen-Dechent, P. L. Weissberg, and C. M. Shanahan Human Vascular Smooth Muscle Cells Undergo Vesicle-Mediated Calcification in Response to Changes in Extracellular Calcium and Phosphate Concentrations: A Potential Mechanism for Accelerated Vascular Calcification in ESRD J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2857 - 2867. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. De Celle, J. P. Cleutjens, W. M. Blankesteijn, J. J. Debets, J. F. Smits, and B. J. Janssen Long-term structural and functional consequences of cardiac ischaemia-reperfusion injury in vivo in mice Exp Physiol, September 1, 2004; 89(5): 605 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schoppet, N. Al-Fakhri, F. E. Franke, N. Katz, P. J. Barth, B. Maisch, K. T. Preissner, and L. C. Hofbauer Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Monckeberg's Sclerosis and Atherosclerosis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4104 - 4112. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O'Sullivan, S. D Scott, N. McCarthy, N. Figg, L. M Shapiro, P. Kirkpatrick, and M. R Bennett Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy Cardiovasc Res, December 1, 2003; 60(3): 673 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Collett, A. Wood, M. Y. Alexander, B. C. Varnum, R. P. Boot-Handford, V. Ohanian, J. Ohanian, Y.-W. Fridell, and A. E. Canfield Receptor Tyrosine Kinase Axl Modulates the Osteogenic Differentiation of Pericytes Circ. Res., May 30, 2003; 92(10): 1123 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Jian, N. Narula, Q.-y. Li, E. R. Mohler III, and R. J. Levy Progression of aortic valve stenosis: TGF-{beta}1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis Ann. Thorac. Surg., February 1, 2003; 75(2): 457 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Proudfoot, J.D. Davies, J.N. Skepper, P.L. Weissberg, and C.M. Shanahan Acetylated Low-Density Lipoprotein Stimulates Human Vascular Smooth Muscle Cell Calcification by Promoting Osteoblastic Differentiation and Inhibiting Phagocytosis Circulation, December 10, 2002; 106(24): 3044 - 3050. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sun, H. Unoki, X. Wang, J. Liang, T. Ichikawa, Y. Arai, M. Shiomi, S. M. Marcovina, T. Watanabe, and J. Fan Lipoprotein(a) Enhances Advanced Atherosclerosis and Vascular Calcification in WHHL Transgenic Rabbits Expressing Human Apolipoprotein(a) J. Biol. Chem., November 27, 2002; 277(49): 47486 - 47492. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L Demer Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids Int. J. Epidemiol., August 1, 2002; 31(4): 737 - 741. [Full Text] [PDF] |
||||
![]() |
C. Top, Z. Cankir, E. Silit, S. Yildirim, and M. Danaci Monckeberg's Sclerosis: An Unusual Presentation: A Case Report Angiology, July 1, 2002; 53(4): 483 - 486. [Abstract] [PDF] |
||||
![]() |
N. P.J Brindle A transcriptional regulator of osteogenesis expressed in calcifying atherosclerotic plaques Cardiovasc Res, November 1, 2001; 52(2): 178 - 180. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |